Flag of the European Union EU Clinical Trials Register Help

Clinical trials for SSRI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    113 result(s) found for: SSRI. Displaying page 6 of 6.
    « Previous 1  2  3  4  5  6 
    EudraCT Number: 2006-004888-54 Sponsor Protocol Number: E2020-G000-326 Start Date*: 2007-12-07
    Sponsor Name:Eisai Ltd
    Full Title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) LT (Completed) ES (Completed) AT (Completed) DK (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000430-42 Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT Start Date*: 2023-06-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004264-21 Sponsor Protocol Number: 1402-0011 Start Date*: 2020-10-07
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI ...
    Medical condition: Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10012401 Depressive disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) SK (Completed) DE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002143-25 Sponsor Protocol Number: M06-873 Start Date*: 2008-11-11
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000337-40 Sponsor Protocol Number: 42847922MDD3001 Start Date*: 2020-09-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003219-22 Sponsor Protocol Number: LMS/SF/UH/0018 Start Date*: 2014-01-27
    Sponsor Name:Hertfordshire Partnership University NHS Foundation Trust [...]
    1. Hertfordshire Partnership University NHS Foundation Trust
    2. University of Hertfordshire
    Full Title: A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10037174 Psychiatric disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002669-20 Sponsor Protocol Number: 03KET2018 Start Date*: 2018-09-18
    Sponsor Name:Celon Pharma SA
    Full Title: A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depre...
    Medical condition: Eketamine, ketamine’s enantiomer, is designed for use in tretment resistant depression, both unipolar and bipolar. Many publications have demonstrated the effect of ketamine/esketamine (mainly admi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004525-26 Sponsor Protocol Number: DAD-Study Start Date*: 2006-03-17
    Sponsor Name:Ruhr Universität Bochum
    Full Title: Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial
    Medical condition: Patients with insulin-treated type 1 or type 2 diabetes mellitus with depression and HbA1c-value >7,5% ICD E14.90 with F32
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022497 Insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003298-28 Sponsor Protocol Number: M06-822 Start Date*: 2007-05-23
    Sponsor Name:Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England)
    Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.
    Medical condition: Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011911-19 Sponsor Protocol Number: QUE/09 Start Date*: Information not available in EudraCT
    Sponsor Name:Ludwig-Maximilian-University of Munich, Department of Psychiatry
    Full Title: Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients
    Medical condition: In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000219-18 Sponsor Protocol Number: PsiloRCT001 Start Date*: 2018-04-09
    Sponsor Name:Imperial College London
    Full Title: Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000665-32 Sponsor Protocol Number: 80202135SJS2001 Start Date*: 2021-11-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) PT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014545-83 Sponsor Protocol Number: C10953/3067/ES/MN Start Date*: 2010-02-24
    Sponsor Name:Cephalon Inc.
    Full Title: A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients wi...
    Medical condition: Patients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060690 Traumatic brain injury LLT
    12.0 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) CZ (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 13:29:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA